Loading patent…
AssigneeBoard of Regents, The University of Texas System
InventorsDavid J. Mangelsdorf, Steven A. Kliewer, Katie C. Coate, Genaro Hernandez
Estimating the term…
The present invention relates to the treatment of secretory disorders, and provides novel methods of treatment of these disorders comprising the administration of fibroblast growth factor 21 (FGF21) or derivatives thereof. The methods of the invention are useful in conditions including exocrine pancreatic insufficiency (EPI), for example EPI resulting from cystic fibrosis, alcoholism, pancreatitis, pancreatic cancer, gallstones, celiac disease, high triglycerides, or lupus. The methods of the present invention find further utility in the treatment of salivary flow disorders, for example Sjorgen's syndrome, and the treatment of EPI or pancreatitis resulting from surgical procedures.
A method of reducing endoplasmic reticulum (ER) stress in the exocrine pancreas of a human subject suffering from exocrine pancreatic insufficiency (EPI), comprising administering to said subject a therapeutically sufficient amount of fibroblast growth factor 21 (FGF21).
Dependencies are inferred from the claim text.